#decarbonization #India #Sustainability Report #Piramal Pharma #Bombay

Piramal Pharma's 2025 Sustainability Report

Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, unveiled its fourth annual sustainability report for the fiscal year 2025, themed "Responsible Innovation and Sustainable Growth." This comprehensive document outlines the company's measurable progress and reinforced commitments across four strategic pillars: business resilience, quality and excellence, responsible operations, and stakeholder focus.

The report emphasizes Piramal Pharma's core belief of "doing well and doing good," showcasing how the company integrates responsible practices throughout its global operations. This includes enhancing governance and ethics, accelerating climate action, promoting diversity and inclusion, and creating social impact through partnerships. The sustainability report underwent an external audit by DNV, ensuring its credibility and transparency.

Business Resilience

Piramal Pharma has taken significant steps in strengthening its business resilience. Notably, 50% of the board members are independent, with a commendable 30% representation of women, surpassing legal requirements. The company reported zero data breaches, achieving 100% compliance in code of conduct training. Additionally, 26.5% of crucial suppliers are evaluated based on sustainability criteria, with plans to enhance the capacity of 30% of these suppliers by the end of FY2026.

Quality and Excellence

In terms of quality, Piramal Pharma demonstrated excellence with 36 successful regulatory inspections, including two by the U.S. FDA. The company conducted 165 customer audits worldwide. The digital transformation continues through initiatives like Catalyst NxGen (S/4HANA), establishing 17 governance dashboards to improve agility and scalability. High customer satisfaction rates were achieved, with 85% in the contract development and manufacturing organization (Piramal Pharma Solutions) and 87% in Critical Care.

Responsible Operations

A pivotal aspect of the report is the decarbonization efforts undertaken by Piramal Pharma. The company recorded a 6% decrease in scope 1 and 2 emissions year-on-year, while increasing renewable energy use by 7.8%, with 20.2% of total energy sourced from bioenergy. Impressively, there were no disposal of hazardous waste, and the company aims to recycle 90% of non-hazardous waste. Water management practices saved 210,000 cubic meters of freshwater.

Moreover, Piramal Pharma engaged in biodiversity initiatives, planting over 2,000 young trees and maintaining a 30% green cover across its Indian sites. A significant project was completed at Piramal's site in Digwal, India, converting a coal-fired steam boiler to run on renewable biomass briquettes—an essential milestone in the company's sustainability journey.

Stakeholder Focus

Progress in diversity, equity, and inclusion is notable at Piramal Pharma. Women make up 30% of the board, and 20% of the global workforce are women, marking a 2.7% increase year-on-year. Among campus recruits, women comprise 63.3%. All employees have received ESG training. Safety initiatives led to a remarkable 45% reduction in the lost-time injury rate, now at 0.05.

According to Nandini Piramal, Chairperson of Piramal Pharma Limited, "At Piramal Pharma, sustainability is not just a responsibility; it's a deliberate choice defining how we operate and grow. In today's complex environment marked by climate change, regulatory developments, and increasing transparency and ethical behavior expectations, sustainability has become central to long-term value creation. This year, we've made significant strides on the path to decarbonization with measurable emission reductions, increased adoption of renewable energy, and intensified efforts on water management and circularity. Our commitment to diversity, equity, and inclusion has fostered a more open corporate culture, while our corporate social responsibility initiatives have positively impacted over 200 million individuals in aspirational districts. As we continue our responsible innovation and sustainable growth, we remain determined to create long-lasting value for our patients, communities, and the planet we all share."

In alignment with its global sustainability initiatives, Piramal Pharma Limited, in collaboration with the Piramal Foundation, advanced its corporate social responsibility initiatives across 112 ambitious Indian districts during FY2025, focusing on education, community well-being, and women's empowerment. The company invested 53.4 million rupees in upgrading school infrastructure, enhancing teaching capacity, and improving learning outcomes, all while addressing public health challenges and promoting safe water practices. Employee volunteerism amplified impact through tree-planting campaigns, health awareness initiatives, and community immersion projects. Furthermore, Piramal Pharma partnered with the Life Sciences Sector Skill Development Council to launch a women-led skill development program near its Digwal facility and continued to support the Aspirational Bharat Collaborative (ABC) project, aiming to enhance the lives of 100 million citizens in disadvantaged regions by 2047.

The sustainability report adheres to Global Reporting Initiative (GRI) standards and aligns with the frameworks outlined by the Sustainability Accounting Standards Board and the UN Center for Governance, underscoring Piramal Pharma Limited's commitment to sustainable growth, responsible capital allocation, and constructive stakeholder engagement.

For more details, you can access the full report here.

About Piramal Pharma Limited

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) offers a differentiated range of products and services from its 17* development and manufacturing sites worldwide, supported by a global distribution network spanning over 100 countries. The company includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization, Piramal Critical Care (PCC), specializing in complex hospital generics, and Piramal Consumer Healthcare, which markets over-the-counter consumer and wellness products. Additionally, Piramal Pharma Limited has a strategic minority stake in Yapan Bio Private Limited, which operates in the biotherapeutics and vaccine segments.